Gilead’s next-generation HIV drug to be FDA assessed
pharmafile | April 8, 2015 | News story | Research and Development, Sales and Marketing | F/TAF, FDA, Gilead, HIV, Tenofovir Alafenamide, emtricitabine
Gilead Sciences has filed its second new drug application for a new combination HIV treatment with the FDA.
The California-based company submitted for review its investigational HIV treatments – two fixed-dose combinations of two Gilead drugs, emtricitabine and tenofovir alafenamide (F/TAF), for the treatment of HIV-1 infection in adults and children aged 12 years and older.
F/TAF is a novel nucleotide reverse transcriptase inhibitor (NRTI), and late stage trials have found F/TAF is no less effective than an existing Gilead HIV treatment, Stribild (elvitegravir cobicistat tenofovir emtricitabine).
In clinical trials the TAF combination has also shown high antiviral efficacy at a dose less than one-tenth that of Gilead’s Viread (tenofovir disoproxil fumarate, TDF), as well as better renal and bone safety compared to TDF.
Today’s filing is the second F/TAF combination Gilead has submitted to the FDA for review, in November 2014 it filed an NDA for an investigational once-daily single tablet regimen containing elvitegravir, cobicistat, emtricitabine and TAF 10 mg (E/C/F/TAF), and a decision is set for November this year. In the EU Gilead earned approval for this in December last year.
“Gilead has a long history of innovating HIV treatments, and with F/TAF we have the potential to further optimise therapies for HIV patients who face a lifetime of antiretroviral treatment,” says Norbert Bischofberger, executive VP of R&D and chief scientific officer at Gilead.
“With its high antiviral efficacy and favourable safety profile, F/TAF may offer an improved backbone for a new generation of HIV regimens.”
Gilead plans to submit a regulatory application for F/TAF in the European Union in the second quarter of 2015.
Lilian Anekwe
Related Content
Gilead’s HIV treatment meets primary trial endpoint
Gilead has announced positive topline results from its phase 3 ARTISTRY-2 trial, which evaluated a …
Gilead announces first shipments of HIV prevention drug to Eswatini and Zambia
Gilead has announced the first shipments of its HIV prevention drug lenacapavir to Eswatini and …
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
